Integra LifeSciences (NASDAQ:IART) Rating Reiterated by 22nd Century Group

Integra LifeSciences (NASDAQ:IART – Get Rating)‘s stock had its “downgrade” rating reaffirmed by equities researchers at 22nd Century Group in a note issued to investors on Tuesday, Benzinga reports.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. downgraded Integra LifeSciences from a “neutral” rating to an “underweight” rating and cut their price objective for the company from $56.00 to $43.00 in a research note on Wednesday. JMP Securities cut their price objective on Integra LifeSciences from $75.00 to $65.00 in a research note on Thursday, April 27th. Citigroup downgraded Integra LifeSciences from a “neutral” rating to a “sell” rating and cut their price objective for the company from $59.00 to $39.00 in a research note on Tuesday. StockNews.com assumed coverage on Integra LifeSciences in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. Finally, Truist Financial dropped their price target on Integra LifeSciences from $58.00 to $54.00 in a research report on Thursday, May 18th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $51.14.

Integra LifeSciences Stock Down 0.6 %

Shares of IART traded down $0.23 during midday trading on Tuesday, reaching $38.25. 275,373 shares of the stock were exchanged, compared to its average volume of 571,940. Integra LifeSciences has a 12-month low of $37.90 and a 12-month high of $62.99. The firm has a 50 day simple moving average of $53.62 and a 200-day simple moving average of $55.03. The company has a quick ratio of 2.40, a current ratio of 3.65 and a debt-to-equity ratio of 0.86. The company has a market cap of $3.13 billion, a price-to-earnings ratio of 18.57, a P/E/G ratio of 1.21 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART – Get Rating) last posted its quarterly earnings results on Wednesday, April 26th. The life sciences company reported $0.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.74. Integra LifeSciences had a return on equity of 16.29% and a net margin of 11.00%. The company had revenue of $380.85 million during the quarter, compared to the consensus estimate of $373.21 million. During the same period last year, the business earned $0.74 EPS. The business’s quarterly revenue was up 1.1% on a year-over-year basis. Research analysts forecast that Integra LifeSciences will post 3.34 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Lisa Evoli sold 3,767 shares of Integra LifeSciences stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $57.00, for a total transaction of $214,719.00. Following the sale, the executive vice president now owns 18,605 shares of the company’s stock, valued at approximately $1,060,485. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Lisa Evoli sold 3,767 shares of Integra LifeSciences stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $57.00, for a total transaction of $214,719.00. Following the sale, the executive vice president now owns 18,605 shares of the company’s stock, valued at approximately $1,060,485. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael J. Mcbreen sold 1,843 shares of Integra LifeSciences stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $54.29, for a total value of $100,056.47. Following the sale, the executive vice president now directly owns 28,796 shares in the company, valued at approximately $1,563,334.84. The disclosure for this sale can be found here. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Integra LifeSciences

Institutional investors have recently bought and sold shares of the stock. South Dakota Investment Council boosted its stake in Integra LifeSciences by 36.0% in the 4th quarter. South Dakota Investment Council now owns 34,396 shares of the life sciences company’s stock valued at $1,929,000 after buying an additional 9,100 shares in the last quarter. Teza Capital Management LLC raised its position in Integra LifeSciences by 9.7% in the 3rd quarter. Teza Capital Management LLC now owns 8,114 shares of the life sciences company’s stock valued at $344,000 after purchasing an additional 716 shares during the last quarter. Teacher Retirement System of Texas raised its position in Integra LifeSciences by 243.4% in the 3rd quarter. Teacher Retirement System of Texas now owns 40,989 shares of the life sciences company’s stock valued at $1,736,000 after purchasing an additional 29,054 shares during the last quarter. NorthCrest Asset Manangement LLC raised its position in Integra LifeSciences by 2.8% in the 4th quarter. NorthCrest Asset Manangement LLC now owns 14,180 shares of the life sciences company’s stock valued at $795,000 after purchasing an additional 380 shares during the last quarter. Finally, Retirement Systems of Alabama raised its position in Integra LifeSciences by 1.0% in the 3rd quarter. Retirement Systems of Alabama now owns 95,110 shares of the life sciences company’s stock valued at $4,029,000 after purchasing an additional 926 shares during the last quarter. Institutional investors and hedge funds own 87.60% of the company’s stock.

About Integra LifeSciences

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.